PPARGC1A and obesity disorder: A frequent substitution of a glycine to serine amino acid at residue 482 in human PPARGC1A was described in 2001 [11], and has been demonstrated to be associated with diabetes [11-14], hypertension [15-17], and obesity [18,19].